Hepatitis C virus – A new age of antiviral therapy
A wave of new drugs has changed the landscape of hepatitis C virus (HVC) treatment in the last 4-5 years. HCV infection is a major cause of liver cirrhosis, end-stage liver disease and hepatocellular carcinoma. Direct-acting antivirals (DAAs) targeting the HCV RNA-dependent RNA polymerase (RdRp) have shown great success for the treatment of HCV infections. However, the efficacy of DAAs designed to target genotype 1 (G1) HCV against non-G1 viruses has not been characterised fully. Here I overview the changes in the treatment of HCV and investigate the effectiveness of non-nucleoside inhibitors (NNIs) against the HCV RdRp from other genotypes.